Aerovate Therapeutics Inc...
2.47
-0.03 (-1.20%)
At close: Jan 14, 2025, 3:59 PM
2.43
-1.62%
After-hours Jan 14, 2025, 07:49 PM EST
undefined%
Bid 2.24
Market Cap 71.32M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.99
PE Ratio (ttm) -0.83
Forward PE n/a
Analyst Hold
Ask 2.61
Volume 605,787
Avg. Volume (20D) 800,431
Open 2.51
Previous Close 2.50
Day's Range 2.43 - 2.51
52-Week Range 1.25 - 32.41
Beta undefined

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 51
Stock Exchange NASDAQ
Ticker Symbol AVTE

Analyst Forecast

According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $2, which is a decrease of -19.03% from the latest price.

Buy 14.29%
Hold 85.71%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+11.87%
Aerovate Therapeutics shares are trading higher af... Unlock content with Pro Subscription
6 months ago · Source
+8.07%
Aerovate Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.